Adenomyosis
Conditions
Interventions
Hysteroscopic resection combined with LNG-IUS placement group:Hysteroscopic resection combined with LNG-IUS
Sponsors
China Welfare Institute International Peace Maternal and Child Health Care Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Premenopausal women aged 18-50 years; 2. No desire for future fertility and willing to preserve the uterus; 3. MRI-confirmed diagnosis of adenomyosis (junctional zone thickness >12 mm; if 8-12 mm, must meet at least one additional criterion: junctional zone/myometrial thickness ratio >40%, anterior-posterior junctional zone thickness difference >5 mm, or ill-defined junctional zone boundaries/high-signal foci on T1/T2 sequences); 4. With symptom of Menorrhagia (menstrual blood loss visual analogue scale [MVJ] >=5); 5. With or without dysmenorrhea (visual analogue scale [VAS] >0); 6. Uterine cavity depth <10 cm; 7. Signed informed consent form.
Exclusion criteria
Exclusion criteria: 1. Malignant tumors; 2. Concomitant benign diseases requiring hysterectomy; 3. Endometrial atypical hyperplasia; 4. Pregnancy or lactation period; 5. Use of steroid hormones or GnRh-a within 3 months prior to enrollment ; 6. Any contraindications to hysteroscopic surgery or LNG-IUS placement, including: (1) Current or recurrent pelvic inflammatory disease; (2) Lower reproductive tract infections; (3) Congenital or acquired uterine abnormalities (including uterine tumors causing uterine cavity deformation); (4) Progesterone-dependent tumors (reproductive tract or breast tumors); (5) Allergy to active ingredients or excipients; 7. Previous hysteroscopic adenomyosis lesion resection; 8. Chronic use of analgesics due to underlying conditions; 9. Inability to comply with study procedures (e.g., language barriers, psychiatric disorders, inability to attend follow-ups, poor compliance); 10. Severe concurrent medical or surgical conditions; 11. Coexisting deep infiltrating endometriosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MVJ Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient satisfaction with treatment;Side effects;Uterine volume;MVJ Score;Serum CA125?CA199;VAS score of Dysmenorrhea; | — |
Countries
China
Contacts
Public ContactJian Zhang
China Welfare Institute International Peace Maternal and Child Health Care Hospital
Outcome results
None listed